A Phase 3 interventional study of alendronate and denosumab in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.
Among the 51 studies testing alendronate in Osteoporosis, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 3, and was the 24th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Women only
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 15 · Phase 4 17
First in 1997; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 60 across the 51 interventional studies. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 14th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 18 in phase 3, and was the 10th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
1 of the studies testing alendronate in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing alendronate in Osteoporosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to alendronate therapy; contraindications for alendronate therapy include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
Drug: alendronate · Drug: denosumab
When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
Drug: alendronate · Drug: denosumab
Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
Adherence With Treatment in the First Treatment Period
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment.
Time frame: Treatment period 1 (Month 1 to Month 12)
Adherence With Treatment in the Second Treatment Period
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment.
Time frame: Treatment period 2 (Months 13 to 24)
Compliance With Treatment in the First Treatment Period
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).
Time frame: Treatment period 1 (Month 1 to Month 12)
Compliance With Treatment in the Second Treatment Period
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).
Time frame: Treatment period 2 (Month 13 to Month 24)
Persistence With Treatment in the First Treatment Period
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.
Time frame: Treatment period 1 (Month 1 to Month 12)
Persistence With Treatment in the Second Treatment Period
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.
Time frame: Treatment period 2 (Month 13 to Month 24)
Time to Non-adherence to Alendronate Treatment in the First Treatment Period
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.
Time frame: Treatment Period 1 (Month 1 to Month 12)
Time to Non-adherence to Alendronate Treatment in the Second Treatment Period
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.
Time frame: Treatment Period 2 (Month 13 to Month 24)
Time to Non-compliance to Alendronate Treatment in the First Treatment Period
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.
Time frame: Treatment period 1 (Month 1 to Month 12)
Time to Non-compliance to Alendronate Treatment in the Second Treatment Period
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.
Time frame: Treatment period 2 (Month 13 to Month 24)
Time to Non-persistence to Alendronate Treatment in the First Treatment Period
Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.
Time frame: Treatment period 1 (Month 1 to Month 12)
Time to Non-persistence to Alendronate Treatment in the Second Treatment Period
Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.
Time frame: Treatment period 2 (Month 13 to Month 24)
Overall Satisfaction to Study Treatment
Participant satisfaction with their treatment was assessed using question 7 (ie, "Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration \[taking a pill\]; convenience; overall satisfaction") and question 8 (ie, "Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration \[receiving an injection\]; convenience; overall satisfaction") from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: "Not at all Satisfied", "A Little Satisfied", "Moderately Satisfied", "Quite Satisfied", and "Very Satisfied".
Time frame: End of treatment period 1 (Month 12)
Beliefs About Medicines Questionnaire (BMQ): Necessity Score
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis.
Time frame: Baseline, Month 6, Month 12, Month 18 and Month 24
Beliefs About Medicines Questionnaire (BMQ) Concern Score
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis.
Time frame: Baseline and Month 6, Month 12, Month 18, and Month 24
Beliefs About Medicines Questionnaire (BMQ) Preference Score
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other.
Time frame: Baseline and Month 6, Month 12, Month 18, and Month 24
Medication Adherence Rating Scale (MARS) to Alendronate in the First Treatment Period
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.
Time frame: Month 6, Month 12 (treatment period 1)
Medication Adherence Rating Scale (MARS) to Alendronate in the Second Treatment Period
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.
Time frame: Month 18, Month 24 (treatment period 2)
First subject enrolled 03-Oct-07, last subject enrolled 25-Jun-08; First subject crossovered 22-May-08, last subject crossovered 25-Jun-09;
| Milestone | Alendronate in Period 1 Then Denosumab in Period 2 | Denosumab in Period 1 Then Alendronate in Period 2 |
|---|---|---|
| Started | 124 | 126 |
| Received treatment | 119 | 124 |
| Completed | 106 | 114 |
| Not completed | 18 | 12 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Early crossover | 1 | 3 |
| Milestone | Alendronate in Period 1 Then Denosumab in Period 2 | Denosumab in Period 1 Then Alendronate in Period 2 |
|---|---|---|
| Started | 106 | 115 |
| Received treatment | 106 | 110 |
| Completed | 103 | 95 |
| Not completed | 3 | 20 |
| Withdrew: Withdrawal by subject | 0 | 8 |
| Withdrew: Complete out of scheduled visit window | 1 | 2 |
| Withdrew: Adverse event | 1 | 7 |
| Withdrew: Protocol-specified criteria | 0 | 1 |
| Withdrew: Non-compliance | 1 | 2 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment.
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 95 | 111 |
| No | 29 | 15 |
A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment.
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 73 | 98 |
| No | 42 | 8 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 97 | 114 |
| No | 27 | 12 |
Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 78 | 99 |
| No | 37 | 7 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 99 | 114 |
| No | 25 | 12 |
Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.
| Participants | Alendronate | Denosumab |
|---|---|---|
| Yes | 82 | 103 |
| No | 33 | 3 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.
| weeks | Alendronate |
|---|---|
| Time to Non-adherence to Alendronate Treatment in the First Treatment Period | 43.29 ± 1.46 |
Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.
| weeks | Alendronate |
|---|---|
| Time to Non-adherence to Alendronate Treatment in the Second Treatment Period | 39.45 ± 1.89 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.
| weeks | Alendronate |
|---|---|
| Time to Non-compliance to Alendronate Treatment in the First Treatment Period | 43.75 ± 1.42 |
Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.
| weeks | Alendronate |
|---|---|
| Time to Non-compliance to Alendronate Treatment in the Second Treatment Period | 39.97 ± 1.87 |
Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.
| weeks | Alendronate |
|---|---|
| Time to Non-persistence to Alendronate Treatment in the First Treatment Period | 44.59 ± 1.35 |
Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.
| weeks | Alendronate |
|---|---|
| Time to Non-persistence to Alendronate Treatment in the Second Treatment Period | 42.76 ± 1.69 |
Participant satisfaction with their treatment was assessed using question 7 (ie, "Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration \[taking a pill\]; convenience; overall satisfaction") and question 8 (ie, "Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration \[receiving an injection\]; convenience; overall satisfaction") from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: "Not at all Satisfied", "A Little Satisfied", "Moderately Satisfied", "Quite Satisfied", and "Very Satisfied".
| Participants | Alendronate | Denosumab |
|---|---|---|
| Not at all satisfied | 3 | 3 |
| A little satisfied | 1 | 3 |
| Moderately satisfied | 17 | 2 |
| Quite satisfied | 34 | 18 |
| Very satisfied | 59 | 95 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis.
| scores on a scale | Alendronate | Denosumab |
|---|---|---|
| Baseline (n=104, 117) | 3.32 ± 0.52 | 3.26 ± 0.48 |
| Month 6 (n=106, 114) | 3.14 ± 0.53 | 3.31 ± 0.60 |
| Month 12 (n=103, 95) | 3.21 ± 0.51 | 3.17 ± 0.52 |
| Month 18 (n=98, 98) | 3.20 ± 0.53 | 3.28 ± 0.55 |
| Month 24 (n=91, 100) | 3.21 ± 0.62 | 3.22 ± 0.58 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis.
| scores on a scale | Alendronate | Denosumab |
|---|---|---|
| Baseline (n=104, 117) | 2.33 ± 0.48 | 2.43 ± 0.46 |
| Month 6 (n=106, 114) | 2.22 ± 0.51 | 2.12 ± 0.51 |
| Month 12 (n=103, 95) | 2.57 ± 0.48 | 2.51 ± 0.50 |
| Month 18 (n=98, 98) | 2.43 ± 0.58 | 2.24 ± 0.49 |
| Month 24 (n=91, 100) | 2.39 ± 0.58 | 2.18 ± 0.51 |
The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other.
| scores on a scale | Alendronate | Denosumab |
|---|---|---|
| Baseline (n=104, 117) | 2.97 ± 0.40 | 3.47 ± 0.43 |
| Month 6 (n=106, 114) | 3.01 ± 0.53 | 3.72 ± 0.47 |
| Month 12 (n=103, 95) | 2.62 ± 0.50 | 3.43 ± 0.45 |
| Month 18 (n=98, 98) | 2.55 ± 0.56 | 3.77 ± 0.47 |
| Month 24 (n=91, 100) | 2.57 ± 0.65 | 3.80 ± 0.52 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.
| scores on a scale | Alendronate |
|---|---|
| Month 6 (n=109) | 24.3 ± 1.1 |
| Month 12 (n= 100) | 24.4 ± 1.4 |
The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.
| scores on a scale | Alendronate |
|---|---|
| Treatment period 2 Month 6 (n=98) | 23.4 ± 2.0 |
| Treatment period 2 Month 12 (n= 90) | 23.8 ± 1.4 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period 1: Alendronate | — | 5/118 (4.2%) | 24/118 (20.3%) |
| Treatment Period 1: Denosumab | — | 4/125 (3.2%) | 31/125 (24.8%) |
| Treatment Period 2: Alendronate | — | 4/110 (3.6%) | 21/110 (19.1%) |
| Treatment Period 2: Denosumab | — | 4/106 (3.8%) | 13/106 (12.3%) |
| Event | Treatment Period 1: Alendronate | Treatment Period 1: Denosumab | Treatment Period 2: Alendronate | Treatment Period 2: Denosumab |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/118 | 2/125 | 0/110 | 1/106 |
| Pelvic massGeneral disorders | 0/118 | 0/125 | 0/110 | 1/106 |
| Pubis fractureInjury, poisoning and procedural complications | 0/118 | 0/125 | 0/110 | 1/106 |
| Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/118 | 0/125 | 0/110 | 1/106 |
| Cerebrovascular accidentNervous system disorders | 0/118 | 0/125 | 0/110 | 1/106 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/118 | 0/125 | 0/110 | 1/106 |
| Hernia painGeneral disorders | 0/118 | 0/125 | 1/110 | 0/106 |
| Fracture nonunionMusculoskeletal and connective tissue disorders | 0/118 | 0/125 | 1/110 | 0/106 |
| Joint contractureMusculoskeletal and connective tissue disorders | 0/118 | 0/125 | 1/110 | 0/106 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/118 | 0/125 | 1/110 | 0/106 |
| Event | Treatment Period 1: Alendronate | Treatment Period 1: Denosumab | Treatment Period 2: Alendronate | Treatment Period 2: Denosumab |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/118 | 11/125 | 7/110 | 3/106 |
| Back painMusculoskeletal and connective tissue disorders | 10/118 | 5/125 | 3/110 | 4/106 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/118 | 9/125 | 4/110 | 5/106 |
| HeadacheNervous system disorders | 7/118 | 4/125 | 3/110 | 3/106 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/118 | 5/125 | 5/110 | 1/106 |
| Age, Continuous(Years) | Alendronate in Period 1 Then Denosumab in Period 2 | Denosumab in Period 1 Then Alendronate in Period 2 | Total |
|---|---|---|---|
| Mean | 65.3 ± 7.7 | 65.1 ± 7.6 | 65.2 ± 7.6 |
| Sex: Female, Male(Participants) | Alendronate in Period 1 Then Denosumab in Period 2 | Denosumab in Period 1 Then Alendronate in Period 2 | Total |
|---|---|---|---|
| Female | 124 | 126 | 250 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alendronate in Period 1 Then Denosumab in Period 2 | Denosumab in Period 1 Then Alendronate in Period 2 | Total |
|---|---|---|---|
| White or Caucasian | 119 | 115 | 234 |
| Black or African American | 2 | 2 | 4 |
| Hispanic or Latino | 1 | 6 | 7 |
| Asian | 1 | 3 | 4 |
| Japanese | 1 | 0 | 1 |
No study locations are listed for this record.
Ran from Sep 2007 to primary completion in Jun 2009, 21 months.
Results were first posted in Jan 2014, 4 years 7 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 21 months is below that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alendronate · Denosumab